The effect of Pentoxifylline on Liver function tests in Non-alcoholic Fatty Liver Disease Non-diabetic Patients

Pentoxifylline might have a role in the suppression of inflammatory cytokines in non-alcoholic fatty liver disease (NAFLD). The aim of study was to evaluate the effect of Pentoxifylline on liver function tests in non-diabetic subjects with NAFLD.

This clinical trial was performed in 120 NAFLD patients. They were divided to two groups by Balance Block Randomization method. A dietitian in both arms performed regulation of daily calorie intake. Pentoxifylline was prescribed to intervention arm at the dose of 1200 m/g per day. Liver function tests were checked at 2 months interval up to 6 months.

Fifty-four patients in control group and fifty-six ones in Pentoxifylline group were evaluated. The participants mean of age was 36. 65 ± 8. 82 years. The mean aminotransferase levels were not statistically different in two arms at the study period. However، the speed of aminotransferase reduction was faster in Pentoxifylline arm. The mean aminotransferase levels were decreased during the study period in each arm.

Pentoxifylline was not effective in reducing aminotransferase in NAFLD patients.